21ьз╕ C

Xheme Inc. Demonstrates Breakthrough in Bioprocessing Innovation, Driving Higher Cell Density and Biologics Yields

News Provided by ACCESS Newswire2026-01-26

NEWTON, MA / ACCESS Newswire / January 26, 2026 /Xheme Inc., a biopharmaceutical innovator developing advanced technologies for life sciences manufacturing, today announced a breakthrough that could redefine how biological cells are produced and stored. As demand for cost‑reduced biologics intensifies, the company 's proprietary single-use bioprocessing solutions are demonstrating significant improvements in cell density and biologics yields. These advances offer a clear pathway to lower biopharmaceutical manufacturing costs. Xheme 's proprietary 1L single-use bioreactor and cell culture media technologies are enabling significant enhancement in CHO Cell densities and yield of monoclonal antibodies produced in both research and commercial CHO cell lines. Analytes suggest XMA products neutralize cellular ROS, protect lipids from peroxidation, and reduce oxidative demand, promoting cellular longevity and enhanced protein synthesis. These products are currently being evaluated by biomanufacturers.

Xheme Logo

Transforming Bioprocessing: Healthier Cells, and Higher Yields

Xheme combats oxidative stress-the hidden limiter of cell performance-through intelligent single‑use and cell‑culture media technologies, enabling innovations across biopharmaceutical manufacturing, cell therapies, blood storage, and food preservation.

By mitigating oxidative stress, Xheme 's technology enables manufacturers to achieve higher productivity, faster cycle times, and improved scalability without compromising product quality. The resulting gains in yield and efficiency directly translate to more affordable biologic therapies.

"Our bioprocessing solutions are engineered to create a healthier, more stable environment for living cells, " said Kumar Challa, Ph.D., Co-Founder and CEO of Xheme Inc.  "This innovation can meaningfully improve batch consistency and output across the biologics industry, from monoclonal-antibody production to next-generation cell therapies. "

Independent Expert Perspective

Prof. Susan Shrafstein, Professor of Nanoscale Science and Engineering at U.Albany said "Reducing ROS in extended fed‑batch cultures is critical to sustaining viability. Xheme 's products show real promise in extending culture duration, increasing viable cell density and the yield of biologics produced ". Dr. Alexander D. Wissner-Gross, an award-winning industry veteran, entrepreneur, and investor added "As the biopharmaceutical industry faces increasing pressure to reduce costs and improve scalability, material innovation has become a critical frontier. Xheme 's approach to optimizing the cellular micro-environment addresses a fundamental variable in bioprocessing. It is encouraging to see this technology advancing, as the sector urgently needs new solutions that can drive efficiency and higher yields. "

Beyond Bioprocessing: Transforming Blood Storage

In addition to upstream bioprocessing, the same polymer platform underpins applications in blood storage. Xheme 's polymer platform also supports DEHP-free blood-storage solutions that have demonstrated reduced hemolysis and superior metabolic activity, leading to healthier stored blood. These next-generation bags comply with FDA and EU hemolysis standards and are advancing through extensive validation studies.

Institutional Partnerships and Federal Funding

To validate and scale its technology for global adoption, Xheme collaborates with the Vitalant Research Institute, a world-class nonprofit focused on transfusion medicine and blood safety, and is an active member of NIIMBL (the National Institute for Innovation in Manufacturing Biopharmaceuticals), a public-private consortium advancing next-generation manufacturing. Xheme Inc. is a partner along with UMass Lowell, Sartorius, and Lonza in the 2025 NIIMBL Project to develop real-time multi-parameter sensing in Bioprocessing.

Xheme 's innovation pipeline is supported by three NSF-STTR awards (including a recent Phase II grant) and a NASA research grant to evaluate polymer performance under space-radiation conditions. The company holds three issued patents and seven pending patent applications, underscoring the depth of its materials and bioprocess IP portfolio.

Xheme Inc.

About Xheme Inc.

Xheme Inc. is a biopharmaceutical innovation company developing advanced single-use solutions and cell culture media for transformative enhancement in cell productivity, focusing on biopharmaceutical production, storage of vital fluids, and cell therapies. Its proprietary oxygen-scavenging solutions enhance stability, scalability, and yield in bioprocessing, blood storage, and cell-therapy manufacturing. Headquartered in Newton, Massachusetts, Xheme partners with leading academic and industry collaborators to pioneer sustainable, high-impact solutions for biomanufacturing and healthcare.